Early versus delayed photodynamic therapy for chronic central serous chorioretinopathy

Gabriel Katz*, Efrat Gur, Joseph Moisseiev, Ari Leshno

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Central serous chorioretinopathy (CSCR) patients are sometimes referred to Photodynamic Therapy (PDT) with very long-term disease. The purpose of this study was to analyze the results of PDT in CSCR eyes with long-standing disease. Methods: The medical records of the patients that underwent PDT for CSCR between 2009 and 2019 were reviewed. Cases were divided into two groups based on the duration of disease before PDT treatment: early treatment (3 to 6 months) and delayed treatment (longer than 6 months). The treatment was defined as successful when the subfoveal fluid was absorbed during follow-up. Results: The PDT treatment was successful in 76% and 77% of eyes in the early and delayed treatment groups, respectively. Both groups showed significant improvement in central retina measurements at the 3-months follow-up which persisted to the last follow-up visit. The visual acuity (VA) at baseline was significantly worse in the delayed treatment group (0.5 ± 0.26 vs. 0.3 ± 0.24, P = 0.042) and improved in both groups but remained low in the delayed treatment group during the study. Conclusion: We suggest that if CSCR is not spontaneously improving over 3 months the patient should be offered PDT, to prevent VA loss from the long-term presence of subretinal fluid in the macula. PDT is not associated with loss of vision in eyes with chronic CSCR, and can be safely used in eyes with relatively good VA.

Original languageEnglish
Pages (from-to)4055-4065
Number of pages11
JournalInternational Ophthalmology
Volume43
Issue number11
DOIs
StatePublished - Nov 2023
Externally publishedYes

Keywords

  • Central serous chorioretinopathy
  • Long-standing
  • Photodynamic therapy
  • Verteporfin

Fingerprint

Dive into the research topics of 'Early versus delayed photodynamic therapy for chronic central serous chorioretinopathy'. Together they form a unique fingerprint.

Cite this